Meryl A. Waldman, M.D.
Staff Clinican:
Kidney Disease Section, Kidney Diseases Branch
Scientific Focus Areas: Immunology
Professional Experience
- Associate Research Physician, NIDDK, NIH, 2018-present
- Staff Clinician, NIDDK, NIH, 2006-present
- Clinical Instructor, Columbia University, New York Presbyterian Hospital, Glomerular Disease Institute, 2005-2006
- Nephrology Fellowship, Hospital of the University of Pennsylvania, 2001-2005
- Internal medicine-Pediatrics Combined Residency, Baystate Medical Center, 1997-2001
- M.D., Tufts University School of Medicine, 1997
Current Research
The focus of my research is the natural history, pathogenesis, and treatment of immunologically mediated glomerular diseases particularly membranous nephropathy. The goal of my research is to find novel ways to suppress autoimmune responses that lead to kidney disease as well as to find more sensitive methods to monitor disease activity.
Select Publications
- Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
- Szymanski JM, Waldman M, Conry-Cantilena C, West KA.
- J Clin Apher (2019 Aug) 34:495-498. Abstract/Full Text
- Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.
- Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, Fike A, Manna Z, Auh S, Shi Y, Chan D, Carlucci P, Biehl A, Dema B, Charles N, Balow JE, Waldman M, Siegel RM, Kaplan MJ, Rivera J.
- Arthritis Rheumatol (2019 Jul) 71:1135-1140. Abstract/Full Text
Research in Plain Language
I study new combinations of agents that reduce the activity of the immune system to treat individuals with immune-mediated kidney disease in which kidney cells are damaged by immune responses or inflammation.